| FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER.: An article from: Biotech Business | Digitalby Unavailable (Author)
| List Price: | $9.95 | | | Available: | Available for download now |
| | Binding: | Digital | | Publisher: | Worldwide Videotex | | Page Count: | 3 Pages | | Publication Date: | September 01, 2009 |
|
EDITORIAL REVIEWS |
Product Description
This digital document is an article from Biotech Business, published by Worldwide Videotex on September 1, 2009. The length of the article is 829 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.Citation DetailsTitle: FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER.Author: UnavailablePublication: Biotech Business (Newsletter)Date: September 1, 2009Publisher: Worldwide VideotexVolume: 22 Issue: 9 Page: NADistributed by Gale, a part of Cengage Learning |
|
